Visx' European Patent claims limited:
This article was originally published in Clinica
Executive Summary
The European Patent Office has found that eight of Visx' claims for its European ophthalmological patent are invalid. The remaining claims for its Patent No 0218427 - Apparatus for Ophthalmological Surgery - were held allowable. The office upheld Summit Technology's opposition to its excimer laser competitor at the end of October (see Clinica No 679, p 14). In a second patent opposition, the European Patent Office limited the scope of Visx' claims for its European Patent No 0257836B1 on the method and apparatus for performing ophthalmic laser surgery.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.